FDA Warning Letter · #703497
Medivant Health: FDA Warning Letter (April 8, 2025)
Legal name: Tailstorm Health Inc.
Medivant Health received this warning letter on April 8, 2025, from FDA’s Center for Drug Evaluation and Research (CDER). What it cites, and FDA’s own words where we matched them against the letter, are summarized below.
Primary Source
View the original FDA letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailstorm-health-inc-dba-medivant-health-703497-04082025
Summary
- Company
- Tailstorm Health Inc. (dba Medivant Health)
- Letter number
- #703497
- Issue date
- April 8, 2025
- Subject
- Compounding Pharmacy/Adulterated Drug Products
What FDA cited
FDA's letter of April 8, 2025 cites Medivant Health for compounding outside the conditions federal law sets for compounders, under the subject line "Compounding Pharmacy/Adulterated Drug Products". The GLP-1 drugs it names: semaglutide and tirzepatide.
During the inspection, the investigator collected evidence that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. … 1. Your facility’s drug products, such as Semaglutide Injection 1mg/0.2ml and Tirzepatide Injection 2.5mg/0.5ml, did not include the following on the label: “Office Use Only.”
How this letter sits against the other 159
Our reading, from the 160 letters on this register — not part of the FDA’s document.
No other letter on this register carries the date April 8, 2025. The agency acted against this company on its own that day, which is uncommon here — most of the letters we hold arrived in sweeps.
A warning letter is the agency putting a company on notice, not a court finding and not a ban. What it is worth to you is in what it alleges, so read the original on fda.gov rather than the fact that one exists.
The FDA wrote about how this firm compounds. For what the 503A and 503B rules require: 503A vs 503B compounding pharmacies: who oversees your compounded GLP-1.
Our profile of Tailstorm Health covers the same operator.
FDA’s letter of September 9, 2025 to MedClub by Dr. Jenn also cites its recipient for compounding outside the conditions federal law sets for compounders.
What FDA warning letters mean
It is the agency writing to a company to say it believes something that company is doing breaks the Federal Food, Drug, and Cosmetic Act — usually a claim on a website, a labeling choice, or how a drug is being made. The company has about fifteen working days to write back.
Read carefully what it is not. It is not a recall, not a criminal charge, and not a court deciding anyone broke the law. It is the regulator opening a file. Companies frequently answer a letter, fix what was cited, and carry on trading, and when FDA accepts that it can issue a close-out letter. We do not track close-outs, so the presence of a letter on this page tells you what FDA said on one date — not where the matter stands today. Ask the company; they will usually tell you, and how they answer is informative in itself.
Across this market the same three citations recur: claiming a compounded product is equivalent to an approved one, labeling that misleads, and compounding from bulk substances FDA has not cleared under sections 503A and 503B. If you are reading a letter here, it is probably one of those.
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →bmiMD
Starting below a standard dose, with microdose tiers
From $129/mo, prepaid
Get started →Other warning letters in our database
- NativeMed — June 8, 2026
- Clover Meds — June 8, 2026
- Join Josie — February 20, 2026
- Motionpharmacycom — September 10, 2025
- GLP-1 Solution — September 9, 2025
Editorial Disclaimer
This is a public communication from a regulator, and by itself it settles nothing about whether the company broke any law. Corrective action is a common response, and a fair number of letters end in a close-out. Read the whole thing on fda.gov through the link above rather than taking our excerpt as the full picture.
Glossary
The words sellers use, defined. Tap any term.
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- FDA Warning Letter · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory